Pharmaceuticals

Global Avastin (Bevacizumab) Market Expected To Reach $34.13 Billion By 2030 With 9.6% CAGR

May 5, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Growth In Market Value Is Expected For The Avastin (Bevacizumab) Market Between 2026 And 2030?

The avastin (bevacizumab) market size has seen significant growth in recent years. It is anticipated to increase from $7.82 million in 2025 to $8.43 million in 2026, registering a compound annual growth rate (CAGR) of 7.8%. The historical growth of this market can be attributed to the clinical validation of VEGF inhibition, the increasing global cancer burden, extensive label expansion approvals, considerable familiarity among oncologists, and its initial adoption in colorectal cancer.

The avastin (bevacizumab) market is anticipated to show robust expansion over the next few years, with projections indicating it will reach $11.27 million by 2030, exhibiting a compound annual growth rate (CAGR) of 7.5%. This growth throughout the forecast period is attributable to the rise of bevacizumab biosimilars, an expanding patient population in oncology, greater utilization in emerging markets, the demand for cost-effective biologics, and advancements in combination regimen optimization. Significant trends during the forecast period include the sustained use of anti-angiogenic cancer therapies, the broadening application of avastin across numerous cancer types, an increase in combination therapy involving chemotherapy, growing acceptance in ophthalmic indications, and a heightened emphasis on biosimilar competition.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19879&type=smp

What Key Factors Are Affecting The Avastin (Bevacizumab) Market Demand?

The increasing prevalence of cancer is anticipated to boost the growth of the avastin (bevacizumab) market. Cancer is a comprehensive term for various diseases defined by the uncontrolled multiplication and dispersion of abnormal cells within the body. The rising occurrence of cancer is due to factors such as an aging population, changes in lifestyle, and improved detection techniques. Avastin treats cancer by inhibiting VEGF, thereby preventing the formation of blood vessels that deliver oxygen and nutrients to tumors, effectively starving them. For instance, in August 2024, the Macmillan Cancer Support, a UK-based organization, reported that in 2024, more than 3 million people in the UK are living with cancer; this figure is projected to rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Therefore, the growing prevalence of cancer is driving the expansion of the avastin (bevacizumab) market.

What Are The Different Segment Types In The Avastin (Bevacizumab) Market Segment Breakdown?

The avastin (bevacizumab) market covered in this report is segmented –

1) By Dosage: 100 Mg, 400 Mg

2) By Application: Non Squamous Non-Small Cell Lung Cancer, Recurrent Glioblastoma, Cervical Cancer, Colorectal Cell Cancer, Ovarian Cancer, Proliferative Diabetic Retinopathy, Malignant Glioma, Neurofibromatosis, Pancreatic Cancer, Other Applications

3) By Distribution channel: Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

4) By End User: Hospitals, Cancer Supportive Centers, Home Healthcare, Academic And Research Institutes, Other End Users

What Trends Are Shaping The Future Of The Avastin (Bevacizumab) Market?

Major companies operating in the Avastin (bevacizumab) market are prioritizing the expansion of biosimilars, such as high-profile bevacizumab biosimilars, to secure a competitive edge. This biosimilar proliferation indicates a swift increase in the number and accessibility of biosimilar drugs in the market. For instance, in December 2023, Bio Thera Solutions, a China-based biopharmaceutical company, received FDA approval for Avzivi (bevacizumab tnjn), a biosimilar to Avastin, which offers equivalent efficacy, safety, and immunogenicity as the reference product. Furthermore, in July 2024, the European Medicines Agency (EMA) also approved BAT1706 / Avzivi for multiple oncology indications. These advancements are driving greater affordability and broadening patient access. However, they concurrently intensify pricing pressure on the originator, challenge market share, and necessitate robust manufacturing capacity for new entrants.

Who Are The Well-Known Companies In The Avastin (Bevacizumab) Market?

Major companies operating in the avastin (bevacizumab) market are Roche Holding AG

Get The Full Avastin (Bevacizumab) Market Report:

https://www.thebusinessresearchcompany.com/report/avastin-bevacizumab-global-market-report

Which Region Represents The Largest Share Of The Avastin (Bevacizumab) Market?

North America was the largest region in the avastin (bevacizumab) market in 2025. The regions covered in the avastin (bevacizumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Avastin (Bevacizumab) Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/avastin-bevacizumab-global-market-report

Browse Through More Reports Similar to the Global Avastin (Bevacizumab) Market 2026, By The Business Research Company

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Adalimumab Infliximab And Etanercept Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilars-market

Antiviral Combination Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795